Traci King

[Ilana Schlam @IlanaSchlam]

With 6 FDA approvals in breast cancer already in 2026, it was time to update the breast cancer treatment algorithms. It's a great problem to have when innovation is moving so fast that it's hard to keep up #bcsm @OncoAlert @DFCI_BreastOnc

[Paolo Tarantino @PTarantinoMD]

What is the real-world risk of recurrence from HR+/HER2- EBC? In our latest #JNCI article, including data from >7000 pts (Flatiron) we report 7y recurrence rates of 14% for N1 and N0 high-risk pts and up to ~40% in N2-3, supporting use of adjuvant CDK4/6i. https://t.co/HEvBu4lVPq

[Miami Hem/Onc Program Director @HemOncMiami]

🎓 June 30 marks the final day of fellowship for our Class of 2026.

Congratulations to an exceptional group of fellows who have excelled in patient care, research, education, and leadership throughout their training. We are incredibly proud of all they have accomplished and are confident they will continue to make meaningful contributions to oncology and to the patients and communities they serve.

From left to right:
🔹 Dr. Amrit Paudel – Sarcoma & GI Oncology, @SylvesterCancer @univmiami 
🔹 Dr. Ali Al Sbihi @Alsbihi93 – GU Oncology, Monument Health (Mayo Clinic Care Network) 
🔹 Dr. Traci King – Breast Oncology, Ochsner MD Anderson Cancer Center @OchsnerHealth 
🔹Dr. Palash Asawa @palashasawa – Melanoma & GU Oncology, University of Utah Huntsman Cancer Institute @huntsmancancer 
🔹 Dr. Chinmay Jani @Jani_Chinmay – Thoracic Oncology & Phase I/Experimental Therapeutics, @SylvesterCancer @univmiami

Congratulations to the Class of 2026! 🎉 We wish you all the very best as you embark on the next chapter of your careers. Your future institutions and, most importantly, your patients are fortunate to have you.

@Drjhoffmanmiami @GlopesMd @SCCCSarcoma @Latinamd @krill_md @GinaDAmatoMD1 @EmilyJonczak @JTrentMDPhD @PeterHoseinMD @HemeOnline @JacksonHealth

[Coral Olazagasti, MD @COlazagasti]

Incredibly proud of this class of rising oncologists from UMMSM/JMH 👏

Truly a pleasure and joy getting to know and work alongside them

Wishing you all endless success

[Dr Sarah Sammons @drsarahsam]

Big week for breast cancer at #ASCO26. A few highlights from the meeting:

Metastatic
TROPION-Breast02 + ASCENT-03 (TNBC, PD-L1 ineligible): Two practice-changing Trop2 ADC options for 1L. Subsequent analyses confirm benefit. 2 good options.

VIKTORIA-1 (HR+/HER2-, PIK3CA-mutated, 2L post-CDK4/6i): Gedatolisib + fulvestrant beat alpelisib with a much cleaner toxicity profile. Triplet did not add anything with palbociclib. Less hyperglycemia, less diarrhea. Stomatitis remains a challenge. Will be a nice doublet option if approved. IV drug.

SERENA-6 (HR+/HER2-): Switching to camizestrant when ESR1 mutation is detected on ctDNA, before progression, yielded 51% ctDNA clearance vs 1.9%. Compelling biology. Let’s see what the FDA does.

persevERA (HR+/HER2-, 1L): Giredestrant + palbociclib did not beat letrozole + palbociclib (33.1 vs 28.2 mo, p=0.15). The 1L SERD moment has not arrived yet. Metastatic SERD benefit appears limited to ESR1-mutant disease.

Early Stage
lidERA (HR+/HER2-): First new adjuvant endocrine therapy in decades. Giredestrant cuts recurrence risk about 30% across pre and postmenopausal patients in subgroup analyses. Premenopausal patients need OFS. FDA submission underway.

KEYNOTE-522 at 7 years (TNBC, stage II-III): EFS 78.3% vs 69.8%, OS 85.1% vs 77.2%. The benefit is durable and real. But real-world irAE rates up to 54%. We need a biomarker to identify who can safely skip immunotherapy.

OPTIMA (HR+/HER2-, node-positive): Chemo omission non-inferior in low genomic risk node-positive patients including N2 using Prosigna. Practice changing for postmenopausal patients. For premenopausal, the key insight is that chemo benefit in low genomic risk patients is largely driven by ovarian suppression, not cytotoxicity. Still need more premenopausal N2 data. Enroll to OFSET.

OASIS-4 (HR+, on ET): Elizanetant improves hot flashes AND sleep across tamoxifen, AI, and GnRH agonist therapy. Non-hormonal and safe for HR+ patients. An adherence tool we have really needed.

REDUSE (bone mets): Denosumab every 12 weeks after induction is non-inferior to every 4 weeks for skeletal-related events, with less hypocalcemia, less ONJ, and more than 50% reduction in drug costs. Smarter de-escalation with no efficacy tradeoff.

GLP-1 RAs: Real-world data showing 43% reduction in metastatic progression and 30% mortality reduction in HR+/HER2- patients on ET + CDK4/6i. Still observational, but the tumor GLP-1 receptor expression data suggests this is more than just a metabolic effect. Prospective studies needed.

Grateful for the science.

#BreastCancer #BCSM #Oncology #MedTwitter

[Rebecca Shatsky, MD @Dr_RShatsky]

Today was a big day in beast cancer history. The controversy started in premenopausal women by RxPonder is no more. Benefit of chemotherapy in those genomically low risk age 40+ premenopausal patients is due to ovarian suppression. Even in N2 patients, biology wins over stage. The big question is do we all go home and switch to Prosigna???#OPTIMA #ASCO2026 #bcsm #Oncology

[Alejandra Perez, MD @atperez_md]

Very proud of Team Breast Intentions at @TackleCancer @hurricanes_dcc @SylvesterCancer THANK YOU 💕

[Miami Hem/Onc Program Director @HemOncMiami]

A little friendly competition, lots of laughs, and great company 🎳🎅
Secret Santa + bowling night with our amazing fellows @SylvesterCancer !

Happy holidays from our team to everyone. Wishing you all a joyful and restful season ���✨

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

First 4 groups of fellows presenting their work this morning absolutely knocked our socks off, although my group was *obviously* the best! 😉
@OncLive #OncLiveFellowsForum #SABCS25

[Priscila Barreto Coelho, MD @PriscilaBCMD]

@SylvesterCancer Breast Team at #SABCS25 Missing a few of our wonderful teammates, but always so grateful to work with this incredible group!

[Priscila Barreto Coelho, MD @PriscilaBCMD]

🔥 ‼️Hot off the press! Our new paper in The Lancet Regional Health – Americas examines breast cancer survival among Caribbean-born women in Florida. We found differences across countries of birth that may reflect genetic admixture and social determinants of health. @SylvesterCancer
https://t.co/xLJl7OkkR2

[James Hoffman @Drjhoffmanmiami]

Best heme-onc fellows anywhere! Truly a special group- fortunate to be a part of the program @SylvesterCancer @HemOncMiami @Jani_Chinmay @HemOncFellows @univmiami

[Miami Hem/Onc Program Director @HemOncMiami]

Starting 2025 with warmth, laughter, and great company! 🥂🎉 Grateful for a sunny breakfast brunch at our home, celebrating new beginnings with @SylvesterCancer Hem/Onc fellowship family. Cheers to a year of growth and camaraderie! @Maryam_Alasfour @MichaelDurante1

[Elisa Krill-Jackson MD @krill_md]

Neoadjuvant hormonal therapy study #SABCS2024 @Sylvester @SABCSSanAntonio

[Alejandra Perez, MD @atperez_md]

Our incredible team @SylvesterCancer attending @SABCSSanAntonio